Marshall Edwards starts ME-143 Phase I trial
The trial aims to assess the safety and tolerability of intravenous ME-143 in patients with refractory solid tumors. The company expects to recruit around 24 patients with final
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.